tbuckley/cabot-search huggingface dataset:
Exhaled Carbon Monoxide With Waterpipe Use in US Students
Authors: Wael Noor El-Nachef, S. Katharine Hammond
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 2534: Suppression of prostate cancer growth by the Src signaling inhibitor, KXO1 (KX2-391)
Authors: Yahao Bu, Lingqiu Gao, David Hangauer, Irwin H. Gelman
Journal: Cancer Research (2010)

Abstract KXO1 (KX2-391), developed as a Src tyrosine kinase signaling inhibitor, exhibits anti-proliferative activity against broad range of human cancer types in vitro, and has shown low toxicity in completed Phase I trials. We tested whether human and mouse prostate cancer (CaP) cell lines, which display activated levels of Src-family tyrosine kinases such as Src, Fyn and Lyn, could be inhibited by KXO1 compared to the broad tyrosine kinase inhibitor, Dasatinib (BMS-354825). Low nanomolar concentrations (9-75 nM) of KXO1 potently inhibited the proliferation of human CaP cell lines LNCaP, LNCaP-C4-2, PC3-LN4, LAPC-4 and DU145, and the CaP cell line, C2H, isolated from a castration-recurrent lesion in TRAMP mice. In contrast, whereas the GI50 of Dasatinib was equal to KXO1 for PC3-LN4 cells (9 nM), the GI50 for Dasatinib in LNCaP and DU145 cells was 10- and 2.7-fold higher than for KXO1, and Dasatinib failed to inhibit the proliferation of LNCaP-C4-2 cells at 10 μM. KXO1 exhibited a dose-dependent ability to inhibit anchorage-independent growth (AIG) of PC3-LN4, LNCaP and LNCaP-C4-2 cells. In contrast, Dasatinib caused less than 15% inhibition of AIG (compared to vehicle controls) in these CaP lines. Cell death, as measured by DNA fragmentation (Promega Cell Death ELISA kit), was induced after 24 h of KXO1 treatment (2-10X the GI50) of LNCaP and PC3-LN4 cells, but not induced by Dasatinib at 10X GI50 levels. We then tested the efficacy of KXO1 (vs. vehicle) in immunocompetent mice (C57BL/6) bearing small (∼150 mm3) syngeneic TRAMP C2H tumors using several treatment regimens that delivered 10 mg/kg/mouse/day. Mice receiving constant oral dosing (drinking water containing KXO1 in 5% sucrose) showed a 35-40% decrease in tumor growth rate, whereas mice dosed by oral gavage once or twice daily showed initial tumor growths followed by regression. Data will be shown comparing the efficacy of KXO1 against C2H tumors in immunocompetent versus SCID mice. Thus, KXO1 shows anti-CaP activity n vitro and in vivo irrespective of p53, AR or androgen-responsive status. Taken together, these data demonstrate strong preclinical evidence for the treatment of androgen-responsive and castration-recurrent CaP with KXO1. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2534.
Inhibition of replication of hepatitis B virus in transgenic mice following administration of hepatotropic lipoplexes containing guanidinopropyl-modified siRNAs
Authors: Musa D. Marimani, Abdullah Ely, Maximilian C.R. Buff, Stefan Bernhardt, Joachim W. Engels, Daniel Scherman, Virginie Escriou, Patrick Arbuthnot
Journal: Journal of Controlled Release (2015)
Baseline sero-epidemiology of hepatitis B virus infection in children and teenagers in Italy. A survey before mass hepatitis B vaccination
Authors: T. Stroffolini, Maria Chiaramonte, A. Craxì, Elisabetta Franco, Mariella Rapicetta, R. Trivello, D. De Mattia, Ida Mura, Anna Giammanco, G. Rigo, B. Scarpa
Journal: Journal of Infection (1991)
Photosensitizers in Soaps
Authors: Stephen Epstein
Journal: JAMA (1966)

<h3>To the Editor:—</h3> It seems to me that the difference between Dr. Molloy's findings and ours is due to the circumstance that the soap and sensitizer he investigated are different from those studied by Dr. Enta and myself. We investigated cases caused by the<i>white</i>Lifebuoy soap, whereas Dr. Molloy dealt with those sensitized by the<i>green</i>variety. Our sensitizer apparently was tribromsalan, 3,4′,5 tribromosalicylanilide (TBS), whereas in Dr. Molloy's cases the sensitizer was dibromsalan, 4′,5 dibromosalicylanilide, (DBS). My reasons for this conclusion are: The two cases reported in our paper were sensitized by white Lifebuoy; they had never used the colored varieties of this soap. The antiseptic in white Lifebuoy soap is TBS. The main antiseptic of green Lifebuoy soap is DBS. Our conclusion that TBS, or, more exactly, that mixture of isomers of TBS contained in the commercial product, actually can act as a photosensitizer, is
Mitral Valve Prolapse Syndrome
Authors: ANDREW L. MORRIS
Journal: Annals of Internal Medicine (1976)

Comments1 November 1976Mitral Valve Prolapse SyndromeANDREW L. MORRIS, M.D.ANDREW L. MORRIS, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-85-5-681_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: After publication of "Arrhythmias in the Mitral Valve Prolapse Syndrome" (Ann Intern Med 84:656-660, 1976) by DeMaria and co-workers, a colleague warned me that the echocardiography and stress testing laboratories should prepare for an avalanche of patients with suspected mitral valve prolapse syndrome. As our facilities often are already overused and the cost of medical care is of increasing concern to us all, I wish to comment on some possible implications of their study.Arrhythmias are of particular interest in patients with this syndrome because palpitations are a quite frequent complaint and because sudden death has been...References1. DEVEREUXPERLOFFREICHEK RJN: Mitral valve prolapse. Circulation 54:3-14, 1976 CrossrefMedlineGoogle Scholar2. GOOCHVINCENCIOMARANHAO AFV: Arrhythmias and left ventricular asynergy in the prolapsing mitral leaflet syndrome. Am J Cardiol 29:611-620, 1972 CrossrefMedlineGoogle Scholar3. WINKLELOPESFITZGERALD RMJ: Arrhythmias in patients with mitral valve prolapse. Circulation 52:73-81, 1975 CrossrefMedlineGoogle Scholar4. MARTIN C: Mid-systolic click, late systolic murmur syndrome associated with complete heart block. J Electrocardiol 8:191-194, 1975 CrossrefMedlineGoogle Scholar5. SHAPPELLMARSHALLBROWN SCR: Sudden death and familial occurrence of mid-systolic click, late systolic murmur syndrome. Circulation 48:1128-1134, 1973 CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 November 1976Volume 85, Issue 5Page: 681-682KeywordsArrhythmiaEchocardiographyMitral valve prolapse Issue Published: 1 November 1976 PDF DownloadLoading ...
Life Insurance Examinations.
Authors: A. P. Stoner
Journal: JAMA (1904)

Des Moines, Iowa, Sept. 20, 1904. <h3>To the Editor:</h3> —In the issue of September 3 Dr. O. A. Rea mildly rebukes the Des Moines physicians for adopting a fee-bill providing for minor charges of $2 for day visits while a minimum of only $2 is charged for life insurance examinations. Permit me to say that I believe his conclusions regarding low fees for life insurance examinations are well founded. A typographical error, however, made the item read $2 to $5 for day visits, instead of $2 to $3, as provided. The doctor's remarks might lead one to believe that the fees for life insurance examinations have been reduced, which is far from being true. On the other hand, the minimum fee has been advanced 100 per cent. A number of fraternal societies doing business here, and in other states, have a fixed rate of $1 per applicant, which includes, beside
Commentary: Scheme has benefited patients
Authors: A. Compston
Journal: BMJ (2010)

When four drugs were licensed for the treatment of relapsing-remitting multiple sclerosis in the mid-1990s, patients sensed that at last something could be done to modify the course of their illness. But the decision of the National Institute for Health and Clinical Excellence (NICE) that these drugs were not cost effective soon dashed those hopes. Behind the scenes a risk sharing scheme was designed that would provide access to the drugs but without compromising the NICE decision. This threw down a gauntlet to the drug companies: demonstrate a cost per quality adjusted life year (QALY) of £36 000 (€42 000; $53 000) or reduce your prices.1 

The first report on 3686 patients (86% of those recruited) with relapsing-remitting multiple sclerosis in the scheme showed that patients did less well on the licensed therapies than expected from the natural course of multiple sclerosis.2 Several reasons were given why this …
Case 43-1969
Authors: Leland S. McKittrick, Robert E. Scully
Journal: New England Journal of Medicine (1969)

Presentation of Case*A fifty-two-year-old woman was admitted to the hospital because of obstruction of the large bowel.Two and a half years previously she had the onset of repeated episodes of profuse vaginal bleeding; she was postmenopausal. Examination of two uterine curettings revealed no evidence of a malignant tumor, and cytologic examination for neoplastic cells was negative. Six months later she was admitted to another hospital because of recurrent vaginal bleeding. Physical examination was negative except for slight enlargement of the uterus. Laparotomy disclosed that the uterus was somewhat enlarged, with multiple small fibroids, and adherent posteriorly; a hysterectomy . . .
Points: Managing diabetes mellitus
Authors: J. W Todd
Journal: BMJ (1981)

α- Methyltryptamine and α-ethyltryptamine inhibited MAO activity both <i>in vitro</i> and <i>in vivo</i>. <i>In vitro</i> the activities of these indoles were of the same order as that of iproniazid. <i>In vivo</i> they differed from iproniazid in that their effect was reversible. 5-Hydroxy-α-methyltryptamine was less active <i>in vitro</i> than the two other indoles tested and showed no inhibition <i>in vivo</i> in the dose used. α-Methyl and α-ethyltryptamine, but not 5-hydroxy-α-methyltryptamine, caused an central stimulation of rats and mice. This effect correlated with the ability to inhibit MAO. α-Methyltryptamine and 5-hydroxy-α-methyltryptamine inhibited 5-hydroxytryptophan decarboxylase <i>in vitro</i> and <i>in vivo</i> as determined by Woolley9s diarrhea test in mice. Although it is possible for α-methyltryptamine to inhibit both MAO and 5-hydroxytryptophan decarboxylase in vivo the observed effects would indicate that MAO is predominantly affected.
Suggestive Therapeutics vs. Hypnotism.
Authors: Julius Grinker
Journal: JAMA (1903)

Chicago, Sept. 26, 1903. <h3>To the Editor:</h3> —InThe Journal, Sept. 26, 1903, appears an editorial under the above heading, which challenges some comment.... Hypnotism, as now understood by men who have had personal experience with it, is really synonymous with suggestion. The Charcot school is responsible for the term artificial hysterical state occasionally cropping up in medical literature. Charcot conducted his experiments with hypnotism on about a dozen or more hysterical patients which were demonstrated to the whole world in order to prove his theories. The peculiar method used and the frequency with which these patients were hypnotized contributed toward their becoming perfect automatons of unconscious suggestion. Hypnotism as practiced now is nothing else but suggestion administered during a state of greatest susceptibility to suggestion. I can not conceive how you can recommend suggestive therapeutics and condemn hypnosis when to successfully practice the first the second is often an
Retrovirus-Specificity of Regulatory T Cells Is Neither Present nor Required in Preventing Retrovirus-Induced Bone Marrow Immune Pathology
Authors: Inês Antunes, Mauro Tolaini, Adrien Kissenpfennig, Michihiro Iwashiro, Kagemasa Kuribayashi, Bernard Malissen, Kim Hasenkrug, George Kassiotis
Journal: Immunity (2008)

Chronic viral infections of the hematopoietic system are associated with bone marrow dysfunction, to which both virus-mediated and immune-mediated effects may contribute. Using unresolving noncytopathic Friend virus (FV) infection in mice, we showed that unregulated CD4+ T cell response to FV caused IFN-γ-mediated bone marrow pathology and anemia. Importantly, bone marrow pathology was triggered by relative insufficiency in regulatory T (Treg) cells and was prevented by added Treg cells, which suppressed the local IFN-γ production by FV-specific CD4+ T cells. We further showed that the T cell receptor (TCR) repertoire of transgenic Treg cells expressing the β chain of an FV-specific TCR was virtually devoid of FV-specific clones. Moreover, anemia induction by virus-specific CD4+ T cells was efficiently suppressed by virus-nonspecific Treg cells. Thus, sufficient numbers of polyclonal Treg cells may provide substantial protection against bone marrow pathology in chronic viral infections.
Chlamydia pneumoniae infection in adults with chronic cough compared with healthy blood donors
Authors: N.H. Birkebaek, J.s Jensen, T Seefeldt, J. Degn, B Huniche, P.l Andersen, L Ostergaard
Journal: European Respiratory Journal (2000)

In a small uncontrolled study, persistent cough has recently been found to be associated with serological evidence of acute Chlamydia pneumoniae infection. In order to assess whether C. pneumoniae plays a role in chronic cough, the prevalence of C. pneumoniae infection in 201 adult patients with chronic cough was compared with the prevalence in 106 healthy blood donors without respiratory tract symptoms in the preceding 3 months. A microimmunofluorescence antibody test was used to determine C. pneumoniae antibodies in the immunoglobulin (Ig)M, IgG and IgA fractions. Further, nasopharyngeal aspirates from the 201 patients were examined for C. pneumoniae deoxyribonucleic acid by polymerase chain reaction (PCR). As judged by serology, nine patients (4%) and one control (1%) had acute C. pneumoniae infection, and 92 patients (46%) and 42 controls (40%) had previous or chronic C. pneumoniae infection. Of the nine patients with acute infection, three were C. pneumoniae PCR positive, and they all had an IgM antibody titre response. The remaining six patients had either an IgG antibody titre of &gt; or =512 (five patients) or an IgA antibody titre of &gt; or =512 (one patient). None of these six patients had detectable IgM antibodies. The mean cough period for the five IgG positive patients (10.8 weeks) was significantly longer than the mean cough period for the remaining patient population (6.4 weeks; p=0.004). It is concluded that Chlamydia pneumoniae infection was not statistically significantly more prevalent in patients with chronic cough than in healthy blood donors, and that Chlamydia pneumoniae appears to have a minor role in patients with chronic cough. Direct detection of Chlamydia pneumoniae by polymerase chain reaction on nasopharyngeal aspirates is highly correlated with detectable immunoglobulin M antibodies, but in the late stages of prolonged cough serological testing of immunoglobulin G and immunoglobulin A may be more beneficial for obtaining a microbiological diagnosis.
The serum concentration of the third component of complement 1C/ 1A in liver disease
Authors: R. A. Fox, F. J. Dudley, S. Sherlock
Journal: Gut (1971)

Serum C<sub>3</sub> (β<sub>1C</sub>/β<sub>1A</sub>) has been measured in normal individuals and the range found is in agreement with findings of other authors (85-370 mg/100 ml). In 18 patients with acute hepatitis and massive necrosis serum C<sub>3</sub> was consistently reduced to below 50% of normal. In other patients with acute hepatitis the serum C<sub>3</sub> concentration was normal. In the majority of the 150 patients with chronic liver disease serum C<sub>3</sub> concentration was normal. However, 10 patients (six with active chronic hepatitis, four with cryptogenic cirrhosis) had hypocomplementaemia. The reason for the depression is not clear but could reflect either decreased synthesis or increased consumption, or a combination of the two.
P 17 Selective liver targeting of a derivatized antiviral nucleoside analogue by recombinant chylomicrons
Authors: P.C.N. Rensen, N.C.M. van Dijk, E.C. Havelaar, M.K. Bijsterbosch, J.K. Kruijt, Th.J.C. van Berkel
Journal: Journal of Controlled Release (1996)
RFA for Small Breast Cancer — What Tumor Can Be Treated Safely?
Authors: M. Takahashi, M. Hosoda, H. Takahashi, Y. Matsuno, S. Todo
Journal: Cancer Research (2009)

Abstract Breast conserving surgery for small breast cancer has been acceptable as one of standard treatments. However, there are some patients who do not be satisfied with the cosmesis. The aim of this study is to verify the clinical safety and usefulness of the RadioFrequency Ablation (RFA) for small breast cancer without resection. Between January 2006 and Octobar 2007, 20 breast cancer patients were performed RFA with cool-tip RF system after sentinel LN biopsy under general anesthesia. All patients has consented as a clinical research, beforehand. MR mammography was performed after 3 and 6 months of follow-up. All patients were performed postoperative histological examination by 8G-needle mammotome biopsy after 6 months MRI evaluation.Tumor viability after RFA was assessed by hematoxylin -eosin and ssDNA staining. QOL after RFA was assessed both subjectively(QOL-ACD score) and objectively(JBCS cosmesis criterion). Preoperative mammotome revealed 4 patients had DCIS and 16 patients had IDC. The patients median age was 53 years old. The mean greatest dimension of tumors was 1.0 cm (range, 0.5-1.5 cm). MRI showed the dimention of coagulation necrotic area by RFA treatment was 3.5cm (range, 2.5-5.4 cm).All patients have been performed postoperative histlogical examination by 8G mammtome biopsy 6 month after RFA treatment. Coagulation necrosis of the tumor was complete in 20of 20 patients (100%).No patient was troubled skin burn. Neither local and distant recurrence has occurred in all patients (median follow up was 30 month). To treat RFA for breast cancer more safely, we analyzed factors which influenced the size of necrosis. Patient age, body mass index (BMI), background concentration measured by MMG, Fat involvement measured by CT did not influence with the size of nectosis (P=0.21,0.17,0.64,0.40). The state of posterior echo detected by ultrasonography was associated with the size of necrosis (p=0.045). Hence, RFA for the tumor with rich fiber such as scirrhous type tend to make necrosis wider than one with poor fiber such as solid tubular type.Most of patients were satisfied with the cosmesis of the RFA treated breast. Objective QOL score (JBCS cosmesis criterion) showed splendid cosmetic outcome. RFA is one of the effective local treatment for small breast cancer (&amp;lt; 1.5 cm in diameter), and bring breast cancer patients cosmetic satisfaction. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 4119.
Abnormal Cardiac Autonomic Nervous Activity After Right Ventricular Outflow Tract Reconstruction
Authors: Hideo Ohuchi, Hiroshi Suzuki, Keiko Toyohara, Kimiko Tatsumi, Yasuo Ono, Yoshio Arakaki, Shigeyuki Echigo
Journal: Circulation (2000)

There are few studies of cardiac autonomic nervous activity (CANA) in patients with congenital heart disease. Methods and Results-We evaluated CANA in 54 patients after closure of an atrial/ventricular septal defect (group A), 54 patients after successful right ventricular outflow tract reconstruction (RVOTR) (group B1), 35 RVOTR patients with residual stenosis (group B2), and 47 controls. Cardiac parasympathetic nervous activity (PSNA) was estimated by heart rate (HR) change after cholinergic blockade, HR variability, and arterial baroreflex sensitivity (BRS). Cardiac sympathetic nervous activity was estimated by the heart-to-mediastinum (123)I-metaiodobenzylguanidine activity ratio (H/M) and HR increase after isoproterenol infusion (ss). HR response (DeltaHR) and peak oxygen uptake (VO(2)) were measured by exercise test. There was no difference in ss among study groups. Group A exhibited mildly impaired PSNA, which recovered 1 year after surgery, and no change in H/M. Impaired PSNA and low H/M were found in groups B1 and B2 compared with controls (P<0.001), although the PSNA tended to recover 1 year after re-RVOTR. In group B1, PSNA and ss were related to DeltaHR, and BRS correlated inversely with the number of surgical procedures and age at RVOTR and positively correlated with the follow-up period, whereas DeltaHR correlated with peak VO(2) (P<0.01 to 0.001).After RVOTR, postsynaptic ss-sensitivity is maintained and is important in DeltaHR during exercise, as is PSNA, although ventricular sympathetic denervation is common. Impaired PSNA immediately after RVOTR improves with improved DeltaHR and results in future amelioration of aerobic capacity, whereas ventricular sympathetic reinnervation is uncertain.
Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group Study
Authors: I-Ming Chen, Richard C. Harvey, Charles G. Mullighan, Julie Gastier-Foster, Walker Wharton, Huining Kang, Michael J. Borowitz, Bruce M. Camitta, Andrew J. Carroll, Meenakshi Devidas, D. Jeanette Pullen, Debbie Payne-Turner, Sarah K. Tasian, Shalini Reshmi, Catherine E. Cottrell, Gregory H. Reaman, W. Paul Bowman, William L. Carroll, Mignon L. Loh, Naomi J. Winick, Stephen P. Hunger, Cheryl L. Willman
Journal: Blood (2012)
Medicaid Eligibility, Prenatal Care, and the Outcome of Pregnancy-Reply
Authors: Bernard Guyer
Journal: JAMA (1991)

To the Editor.—  The recent excellent article by Piper et al 1 documents the absence of improvements in use of early prenatal care, birth weight, or neonatal mortality with expanded Medicaid eligibility in Tennessee. This study and an accompanying editorial by Guyer 2 describe a variety of reasons for the lack of health status improvement with the removal of financial barriers to obtaining prenatal care.  The results are actually not surprising, but clearly illustrate that policy-makers in government, public health, and medicine have overlooked a vital risk factor for low birth weight and neonatal morbidity and mortality: voluntary, deleterious maternal behavior. Indeed, behaviors such as cigarette smoking, alcohol consumption, illicit drug use, junk food nutrition, obesity, and adolescent pregnancy all affect the newborn's health. No amount of openended or expanded Medicaid funding can correct this.  The data demonstrate that we have reached the point of diminishing returns, with funding directed